NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants will carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions. This capital infusion is significant for NanoViricides as it continues to advance its clinical-stage, broad-spectrum antiviral drug NV-387, which has received orphan drug designation from the U.S. FDA.
The offering highlights investor confidence in NanoViricides' proprietary host-mimetic nanomedicine technology, which aims to develop antivirals that viruses and their variants cannot escape. NV-387, the company's lead candidate, is designed to be a first-line treatment for patients presenting with respiratory viral illnesses. The drug has demonstrated efficacy in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles. The orphan drug designation could provide NanoViricides with 7 years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval, potentially accelerating the drug's path to market.
The proceeds from this offering are expected to support ongoing research and development, including clinical trials for NV-387. NanoViricides' technology platform represents a novel approach to antiviral therapy, focusing on broad-spectrum activity that could address multiple viral threats, including emerging variants. The company's progress is closely watched by investors and public health officials, given the ongoing need for effective treatments against respiratory viruses. The offering details are available in the full press release at https://ibn.fm/Z8Etj. For the latest news and updates on NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
